(Q38095710)

28 August 2017

HCV RNA viral load assessments in the era of direct-acting antivirals (English)

1 reference

28 August 2017

1 reference

Bryan Cobb

1

1 reference

28 August 2017

Paul J Pockros

series ordinal

2

1 reference

28 August 2017

Regis A Vilchez

series ordinal

3

1 reference

28 August 2017

John M Vierling

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

The American Journal of Gastroenterology

28 August 2017

1 reference

28 August 2017

108

1 reference

28 August 2017

4

1 reference

28 August 2017

471-475

1 reference

Virological tools to diagnose and monitor hepatitis C virus infection

28 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Evolution in the sensitivity of quantitative HIV-1 viral load tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Drugs in development for chronic hepatitis C: a promising future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.248

21 January 2018

Identifiers

DOI

10.1038/AJG.2012.248

1 reference

28 August 2017

1 reference